HSBC Holdings’s Kyntra Bio KYNB Stock Holding History

HSBC Holdings’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-600	Closed	-$691K	–	2607
2018 Q1	$691K	Sell	600 -1,000	-63%	-$1.32M	﹤0.01%	1807
2017 Q4	$1.9M	Hold	1,600	–	–	﹤0.01%	1125
2017 Q3	$2.15M	Buy	+1,600	New	+$1.69M	﹤0.01%	1285

Other funds holding KYNB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HSBC Holdings's KYNB Position: Q2 2025 in Review

HSBC Holdings sold out of Kyntra Bio (KYNB) in Q2 2025, closing a stake of 1,199 shares — an estimated $9.51K sold.

HSBC Holdings first reported a position in KYNB in Q4 2016 and held it in 27 quarters. The position peaked at $673K in Q4 2019. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.

HSBC Holdings reported no remaining Kyntra Bio position as of Q2 2025 after selling out during the quarter.
HSBC Holdings sold 1,199 Kyntra Bio shares in Q2 2025, an estimated $9.51K.
HSBC Holdings first reported a position in Kyntra Bio in Q4 2016 and held it in 27 quarters.
HSBC Holdings's Kyntra Bio position peaked at $673K in Q4 2019.
30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.

Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.